Sanofi Genzyme backs further out of deal with Voyager

18 June 2019
voyagertherapeutics_company

Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics (Nasdaq: VYGR), as the companies yesterday announced a restructuring of their gene therapy relationship.

Under the terms of the agreement, Voyager re-gains worldwide rights to the VY-HTT01 Huntington’s disease program and ex-US rights to the VY-FXN01 Friedreich’s ataxia program. The ex-US rights to VY-FXN01 are, in turn, transferred from Voyager to Neurocrine Biosciences (Nasdaq: NBIX) under the terms of the collaboration agreement between Voyager and Neurocrine Biosciences announced in January 2019.

Despite the mixed news, Voyager’s shares, which fell 3.4% pre-market, ended trading on Monday up 10.35% at $26.75. Sanofi was up 2.7% at 77.52 euros by late afternoon today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology